From industry to healthcare: accelerating positive impact in Asia-Pacific
Published on April 13, 2026
4 minutes
To fulfill new reliability and performance requirements in Asia, Air Liquide is deploying high-impact solutions across its entire value chain. In Industry, relying on its engineering base in China, the Group is expanding its industrial asset base and accelerating decarbonization through electrification. In Healthcare, the same logic underlines services and technologies designed to help healthcare professionals to focus on their medical mission and to improve patient treatment adherence over time, combining continuity of support with proactive monitoring.
Thirty years of engineering in China: a milestone powering the next chapter
2025 marked the 30th anniversary of Air Liquide's Engineering & Construction (E&C) presence in China: a milestone that reflects three decades of projects delivered, production capabilities built, and trust earned with customers and partners.
Since 1995, E&C China has combined local expertise with robust industrial capacity to deliver reliable project execution across the country and beyond, with safety and performance as non-negotiable fundamentals. This anniversary was the occasion to celebrate the dedication, resilience and ingenuity of the people behind this journey, and the long-standing partnerships that made it possible.
Air Liquide's engineering teams in China operate through a center in Hangzhou and a manufacturing workshop in Yantai, providing a strong local base to execute complex industrial and technological programs. With this foundation, the focus now turns to the future: accelerating innovative solutions for industrial decarbonization and supporting the fast-growing semiconductor market.
Strengthening Eastern China’s gas platform with the acquisition of Hangzhou Best Gas Co.
Air Liquide has recently completed the acquisition of Hangzhou Best Gas Co., Ltd. in Hangzhou (Zhejiang Province), the Group's largest acquisition in the country. The deal expands Air Liquide's industrial and medical gases footprint in Eastern China by adding two Air Separation Units (ASU) and various associated assets.
Hangzhou Best brings a broad portfolio — from liquid oxygen, nitrogen and argon to high-purity hydrogen, medical gases, and electronic-grade and food-grade gases — and a scale anchored by annual revenue of over 400 million renminbi (around 50 million euros). The company serves over 2,500 customers across China, particularly in the East, and around 400 employees are joining Air Liquide and will continue operating three sites in Hangzhou.
Air Liquide already operated an ASU, a filling center and a dozen small on-site gas production units across the region. This acquisition will create logistics and sourcing synergies and strengthen the Group's position in a key industrial basin.
Electrifying oxygen production in Shaanxi to cut CO₂ emissions and grow capacity
Air Liquide will invest around 25 million euros to revamp and electrify its ASU in Yulin, in the Shaanxi Province, a key industrial hub in China.
The existing steam-driven ASU will be converted into a more efficient electricity-driven system. This shift will deliver an immediate CO₂ reduction of 224,000 tonnes per year, and, as low-carbon electricity is gradually sourced from the start of operations, the total annual reduction is expected to reach 550,000 tonnes of CO₂. Beyond decarbonization, the upgrade will increase oxygen production capacity by 10%. The electrified unit is expected to be operational by end-2027, with Air Liquide ensuring continuity of supply in the meantime.
The Group is already applying this approach at scale in China, having electrified two facilities in Tianjin. This track record strengthens the Group's ability to deploy proven electrification solutions to support customers' decarbonization pathways across the country.
Sleep360, a value-based sleep apnea pathway built around outcomes
While the home healthcare market in South Korea is based on a price-competitive model mainly driven by primary care, Air Liquide launched Sleep360 alongside hospitals, a service-based offer prioritizing patient outcomes, long-term adherence and quality of life designed to maintain sleep apnea patients on therapy with the support of a digital platform.
At the heart of the Sleep360 offer is proactive remote monitoring, enabled by a 360° view of the patient journey: real-time adherence data and clinical indicators enable early intervention by Air Liquide's teams before patients deviate from their prescribed treatment. Among the encouraging results, the dropout rate fell, while most patients no longer required physical home visits. Physicians also report stronger trust and more sustainable prescribing patterns, signs that prioritizing value over price can reshape patient care in a competitive market.